padnarsertib   Click here for help

GtoPdb Ligand ID: 10593

Synonyms: KPT-9274 | KPT9274 | PAK4-IN-1
PDB Ligand
Compound class: Synthetic organic
Comment: KPT-9274 is a small molecule that has reported inhibitory activity against PAK4 and NAMPT [3,6]. It is being developed by Karyopharm Therapeutics for anti-cancer efficacy in solid tumours [2,5] and in B cell malignancies [7]. KPT-9274 is suggested to act as an allosteric modulator of PAK4 that does not interfere with the enzyme's kinase activity (in contrast to the type 1 ATP-competitive PAK kinase inhibitor PF-3758309). It produces dose-dependent antitumour effects in solid and haematologic cell lines at low nanomolar concentrations [1]. KPT-9274 is claimed as example 728 in patent WO2015003166A1 [4].
The chemical structure of KPT-9274 is identical to that which was submitted to the WHO for the INN padnarsertib (proposed INN list 126, Jan 2022).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 101.46
Molecular weight 610.22
XLogP 7.1
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NCc1cc2c(o1)c(cc(c2)c1ccc(cc1)C(=O)N1CCC(CC1)(F)F)c1ccc(cc1)F)C=Cc1ccc(nc1)N
Isomeric SMILES O=C(NCc1cc2c(o1)c(cc(c2)c1ccc(cc1)C(=O)N1CCC(CC1)(F)F)c1ccc(cc1)F)/C=C/c1ccc(nc1)N
InChI InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+
InChI Key MRFOPLWJZULAQD-SWGQDTFXSA-N
No information available.
Summary of Clinical Use Click here for help
KPT-9274 has begun Phase 1 clinical evaluation to ascertain its efficacy as a treatment for non-Hodgkin lymphoma and for solid tumours. See clinical trial NCT02702492 for full details.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02702492 PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Phase 1 Interventional Karyopharm Therapeutics Inc